Batch release: QP certification and release of a batch for sale

Batch release is the step where a qualified person certifies that a batch meets its marketing authorisation and GMP, so it can be sold in the EU.

Also known as: QP release, QP certification, batch certification, EU batch release

3 min readUpdated

Reviewed by Gosia Luksza, CEO at Regunaut

At a glance

Legal basis
Article 51 of Directive 2001/83/EC; Annex 16 of EudraLex Volume 4
Done by
A qualified person at an EEA site that holds an MIA
Imports
Retested in the EU unless a mutual recognition agreement applies
Named in
The marketing authorisation and the package leaflet

How it works

Article 51 of Directive 2001/83/EC requires every batch of a medicinal product to be certified by a qualified person before it is placed on the market. For a batch manufactured in the EU, the QP certifies that it was manufactured and checked in accordance with the law of the Member State and the requirements of the marketing authorisation. For a batch coming from a third country, the QP certifies that it has undergone in a Member State a full qualitative analysis, a quantitative analysis of at least all the active substances and all the other tests needed to ensure its quality in accordance with the marketing authorisation. The certification is entered in a register or equivalent document that is kept for at least five years, and a certified batch can then move between Member States without being tested again.

Annex 16 of EudraLex Volume 4, in the revised version in operation since April 2016, describes how this works. It separates certification, which is the QP's decision, from release, the change of stock status that follows. Before certifying, the QP must be satisfied that every manufacturing and testing site is covered by the marketing authorisation and holds the right authorisation, that the active substance was made under GMP and its supply chain is documented, that deviations have been assessed, and that the batch matches the registered specification and process. Where several sites take part, each site's QP can confirm its own step, and the certifying QP relies on those confirmations and on written agreements. Batch release is distinct from the manufacturing and importation authorisation, which is the site's licence to perform it.

For imports the retesting requirement falls away where the EU has made appropriate arrangements with the exporting country, in practice a mutual recognition agreement that covers the product type, as with Switzerland, Canada, Japan, Australia and New Zealand. The QP still certifies each batch, on the basis of the manufacturer's documentation. Vaccines and medicines derived from human blood or plasma can also be subject to official control authority batch release under Article 114, in which an official medicines control laboratory tests the batch before it is marketed. In the dossier, the site responsible for batch release in the EEA is named in the application, in Annex II of centrally authorised products and in the package leaflet, so moving batch release to another site is a variation and a leaflet change.

What goes wrong

A batch is certified although a manufacturing or testing site in its history is not yet approved in the marketing authorisation, or a variation is approved in some Member States and not in the one the batch is released for; imported batches are released on the third-country certificate of analysis where no mutual recognition agreement covers the product; the batch release site named in the leaflet is not the site that certified the batch; the QP relies on another site's confirmation without a written agreement or an audit behind it; a transfer of the marketing authorisation or a change of importer leaves no EEA site named for release; and stock is shipped to a warehouse in saleable status before the certification is signed.

What teams do with it in Regunaut

One job in the platform that turn on Batch release, each part of a wider workflow.

Batch release: common questions

What is the difference between QP certification and batch release?

Certification is the qualified person's signed confirmation that the batch complies with GMP and the marketing authorisation. Release is the step that follows, when the stock status changes so that the batch can be sold or supplied. Annex 16 of the EU GMP guide treats them separately: a batch cannot be released before it is certified.

Do imported medicines have to be retested in the EU?

As a rule, yes. Article 51(1)(b) of Directive 2001/83/EC requires each imported batch to undergo a full qualitative and quantitative analysis in a Member State before a qualified person certifies it. The testing is not required where a mutual recognition agreement between the EU and the exporting country covers the product; the QP then certifies on the manufacturer's batch documentation.

Can batch release take place outside the EU?

No. Certification for the EU market must be done by a qualified person at a site in the EEA that holds a manufacturing and importation authorisation covering batch certification. Manufacture and testing can take place in third countries, but the certifying site, which is named in the marketing authorisation and the package leaflet, must be in the EEA.

Sources

  1. EUR-Lex: Directive 2001/83/EC on the Community code relating to medicinal products for human use
  2. European Commission: EudraLex Volume 4, Annex 16, Certification by a Qualified Person and Batch Release
  3. European Commission: EudraLex Volume 4, Good Manufacturing Practice (GMP) guidelines

Put your Batch release question to Workbench

Workbench answers regulatory questions from EUR-Lex, EMA, national agencies and your own documents, with every claim linked to its source. Start free with welcome credits.